BioRestorative Therapies Inc (NASDAQ:BRTX) Director John M. Desmarais bought 80,000 shares of BioRestorative Therapies stock in a transaction on Monday, September 26th. The shares were acquired at an average price of $3.00 per share, for a total transaction of $240,000.00. Following the completion of the acquisition, the director now owns 455,000 shares of the company’s stock, valued at approximately $1,365,000. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

BioRestorative Therapies Inc (NASDAQ:BRTX) opened at 3.30 on Monday. The company’s market capitalization is $14.13 million. BioRestorative Therapies Inc has a 12-month low of $2.61 and a 12-month high of $6.09. The firm’s 50-day moving average price is $3.27 and its 200 day moving average price is $3.69.

About BioRestorative Therapies

BioRestorative Therapies, Inc develops therapeutic products and medical therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The Company offers human and plant stem cell derived cosmetic and skin care products. Its programs relate to the treatment of disc/spine disease and metabolic disorders and include Disc/Spine Program (brtxDISC) and Metabolic Program (ThermoStem).

5 Day Chart for NASDAQ:BRTX

Receive News & Ratings for BioRestorative Therapies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies Inc and related companies with's FREE daily email newsletter.